Prostate radiotherapy in the era of intensified systemic treatment of metastatic prostate cancer
For men with low-volume de novo metastatic castration-sensitive prostate cancer, radiotherapy to the prostate is a standard of care option due to the significant improvement in overall survival reported in the STAMPEDE trial.1 The HORRAD trial2 similarly investigated prostate radiotherapy in men with bone-only metastatic disease, but did not find a significant improvement in overall survival for patients with up to five bone metastases, likely because the trial overall was underpowered (low numbers in the group of patients with low-volume metastatic disease specifically)was underpowered.
